Cara Therapeutics to Present at May Investor Conferences
May 03 2022 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq: CARA), an early
commercial-stage biopharmaceutical company leading a new treatment
paradigm to improve the lives of patients suffering from pruritus,
today announced that Christopher Posner, President and Chief
Executive Officer, will present at the following investor
conferences in May:
BofA Securities 2022 Healthcare
ConferenceTuesday, May 10, 2022, at 2 p.m. PT / 5 p.m.
ET
H.C. Wainwright Global Investment
ConferenceWednesday, May 25, 2022, at 2:30 p.m. ET
Webcasts of the presentations can be accessed
under "Events & Presentations" in the News & Investors
section of the Company's website at www.CaraTherapeutics.com.
Archived webcast recordings will be available on the Cara website
for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is an early commercial-stage biopharmaceutical
company leading a new treatment paradigm to improve the lives of
patients suffering from pruritus. The Company’s novel KORSUVA™
(difelikefalin) injection is the first and only FDA-approved
treatment for moderate-to-severe pruritus associated with chronic
kidney disease in adults undergoing hemodialysis. The Company is
developing an oral formulation of difelikefalin and has initiated
Phase 3 programs for the treatment of pruritus in patients with
non-dialysis dependent advanced chronic kidney disease and atopic
dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin) are
ongoing in primary biliary cholangitis and notalgia paresthetica
patients with moderate-to-severe pruritus. For more information,
visit www.CaraTherapeutics.com and follow the company on Twitter,
LinkedIn and Instagram.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara
Therapeutics203-406-3700investor@caratherapeutics.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024